Characteristics | Total (N=488) |
Age (years), mean (SD) | 55.3 (14.4) |
Gender (male), n (%) | 218 (44.9) |
Type of disease, n (%) | |
UC | 246 (50.4) |
CD | 233 (47.8) |
IBD-U | 9 (1.8) |
Disease duration (years), mean (SD) | 18.4 (10.3) |
Therapy, n (%) | |
No treatment | 132 (27.1) |
Mesalamine | 227 (46.5) |
Corticosteroids | 13 (2.7) |
Azathioprine | 32 (6.6) |
Anti-tumour necrosis factor-α | 75 (15.4) |
Infliximab | 21 (4.3) |
Adalimumab | 49 (10.0) |
Golimumab | 5 (1.0) |
Vedolizumab | 28 (5.7) |
Ustekinumab | 21 (4.3) |
Tofacitinib | 2 (0.4) |
Previous COVID-19, n (%) | 42 (8.6) |
COVID-19 vaccine, n (%) | |
Only one dose | 55 (11.3) |
Two doses | 433 (88.7) |
COVID-19 vaccine type, n (%) | |
BNT162b2 (Pfizer) | 320 (65.6) |
mRNA-1273 (Moderna) | 150 (30.7) |
Vaxzevria (AstraZeneca) | 18 (3.7) |
Remission of disease, n (%) | 397 (81.4) |
State of mind before vaccine, n (%) | |
Unconcerned | 118 (24.2) |
Afraid | 23 (4.7) |
Anxious | 89 (18.2) |
Wishful | 246 (50.4) |
Glad | 12 (2.5) |
CD, Crohn’s disease; IBD-U, undetermined IBD; UC, Ulcerative Colitis.